Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05151471 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
A Phase 3 study, sponsored by Tanabe Pharma America.
- Terminated
- Registry status
- Phase 3
- Development phase
- 202
- Enrollment target
NCT05151471 is a Phase 3 study that was terminated before completion, run by Tanabe Pharma America. The registered enrollment target is 202 participants.
The verdict
NCT05151471, a Phase 3 study, was terminated before completion, sponsored by Tanabe Pharma America.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 202 participants
- Enrollment target
Study Summary
To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS), based on the time from the randomization date in Study MT-1186-A02 to at least a 12-point decrease in Revised ALS Functional Rating Score (ALSFRS-R) or death, whichever happens first, over the course of the study or until oral edaravone is commercially available in that country
Interventions
- DRUG Placebo
- DRUG MT-1186
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2022-01-11 |
| Est. Completion | 2023-09-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05151471
The ClinicalTrials.gov registry entry for NCT05151471 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tanabe Pharma America, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05151471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05151471 about?
NCT05151471 is a clinical study titled "Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS". To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS), based on the time from the randomization date in Study MT-1186-A02 to at least a 12-point decrease in Revised ALS Functional Rating Score (ALSFRS-R) or death, whichever...
What is the current status of trial NCT05151471?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 202 participants. The study started on 2022-01-11. Estimated completion is 2023-09-29.
What interventions are being tested in trial NCT05151471?
The interventions under investigation include: Placebo (DRUG), MT-1186 (DRUG).
Who is sponsoring clinical trial NCT05151471?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.